ID   IF4G2_HUMAN             Reviewed;         907 AA.
AC   P78344; O60877; P78404; Q0VH00; Q0VH01; Q2NKW9; Q49A79; Q53EU1; Q58EZ2;
AC   Q8NI71; Q96C16;
DT   30-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   28-JUN-2023, entry version 206.
DE   RecName: Full=Eukaryotic translation initiation factor 4 gamma 2;
DE            Short=eIF-4-gamma 2;
DE            Short=eIF-4G 2;
DE            Short=eIF4G 2;
DE   AltName: Full=Death-associated protein 5;
DE            Short=DAP-5;
DE   AltName: Full=p97;
GN   Name=EIF4G2 {ECO:0000312|HGNC:HGNC:3297};
GN   Synonyms=DAP5 {ECO:0000303|PubMed:9032289}; ORFNames=OK/SW-cl.75;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   IDENTIFICATION OF A NON-AUG INITIATOR START CODON, AND INTERACTION WITH
RP   EIF4A AND EIF3.
RC   TISSUE=Placenta {ECO:0000269|PubMed:9049310};
RX   PubMed=9049310; DOI=10.1093/emboj/16.4.817;
RA   Imataka H., Olsen H.S., Sonenberg N.;
RT   "A new translational regulator with homology to eukaryotic translation
RT   initiation factor 4G.";
RL   EMBO J. 16:817-825(1997).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND INTERACTION
RP   WITH EIF4A.
RC   TISSUE=Liver {ECO:0000269|PubMed:9030685};
RX   PubMed=9030685; DOI=10.1101/gad.11.3.321;
RA   Yamanaka S., Poksay K.S., Arnold K.S., Innerarity T.L.;
RT   "A novel translational repressor mRNA is edited extensively in livers
RT   containing tumors caused by the transgene expression of the apoB mRNA-
RT   editing enzyme.";
RL   Genes Dev. 11:321-333(1997).
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney {ECO:0000269|PubMed:9032289};
RX   PubMed=9032289; DOI=10.1128/mcb.17.3.1615;
RA   Levy-Strumpf N., Deiss L.P., Berissi H., Kimchi A.;
RT   "DAP-5, a novel homolog of eukaryotic translation initiation factor 4G
RT   isolated as a putative modulator of gamma interferon-induced programmed
RT   cell death.";
RL   Mol. Cell. Biol. 17:1615-1625(1997).
RN   [4] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Retinal pigment epithelium, Skin {ECO:0000269|PubMed:15489334},
RC   and Testis {ECO:0000269|PubMed:15489334};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7] {ECO:0000305}
RP   PROTEIN SEQUENCE OF 1-12, AND ACETYLATION AT MET-1.
RC   TISSUE=Platelet {ECO:0000269|PubMed:12665801};
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 679-907.
RC   TISSUE=Colon adenocarcinoma {ECO:0000269|Ref.8};
RA   Shichijo S., Itoh K.;
RT   "Identification of immuno-peptidmics that are recognized by tumor-reactive
RT   CTL generated from TIL of colon cancer patients.";
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [9] {ECO:0000305}
RP   INTERACTION WITH MKNK1.
RX   PubMed=9878069; DOI=10.1093/emboj/18.1.270;
RA   Pyronnet S., Imataka H., Gingras A.-C., Fukunaga R., Hunter T.,
RA   Sonenberg N.;
RT   "Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to
RT   phosphorylate eIF4E.";
RL   EMBO J. 18:270-279(1999).
RN   [10] {ECO:0000305}
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=11511540; DOI=10.1101/gad.889201;
RA   Pyronnet S., Dostie J., Sonenberg N.;
RT   "Suppression of cap-dependent translation in mitosis.";
RL   Genes Dev. 15:2083-2093(2001).
RN   [11] {ECO:0000305}
RP   FUNCTION.
RX   PubMed=11943866; DOI=10.1073/pnas.082102499;
RA   Henis-Korenblit S., Shani G., Sines T., Marash L., Shohat G., Kimchi A.;
RT   "The caspase-cleaved DAP5 protein supports internal ribosome entry site-
RT   mediated translation of death proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5400-5405(2002).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [14]
RP   INTERACTION WITH DAZAP2.
RX   PubMed=17984221; DOI=10.1128/mcb.01226-07;
RA   Kim J.E., Ryu I., Kim W.J., Song O.K., Ryu J., Kwon M.Y., Kim J.H.,
RA   Jang S.K.;
RT   "Proline-rich transcript in brain protein induces stress granule
RT   formation.";
RL   Mol. Cell. Biol. 28:803-813(2008).
RN   [15]
RP   INTERACTION WITH MIF4GD.
RX   PubMed=18025107; DOI=10.1128/mcb.01500-07;
RA   Cakmakci N.G., Lerner R.S., Wagner E.J., Zheng L., Marzluff W.F.;
RT   "SLIP1, a factor required for activation of histone mRNA translation by the
RT   stem-loop binding protein.";
RL   Mol. Cell. Biol. 28:1182-1194(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-514, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-508, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-395 AND SER-902, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-902, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; THR-89; SER-443 AND
RP   THR-508, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-508, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-360; LYS-431 AND ARG-505, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-575, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Appears to play a role in the switch from cap-dependent to
CC       IRES-mediated translation during mitosis, apoptosis and viral
CC       infection. Cleaved by some caspases and viral proteases.
CC       {ECO:0000269|PubMed:11511540, ECO:0000269|PubMed:11943866,
CC       ECO:0000269|PubMed:9032289, ECO:0000269|PubMed:9049310}.
CC   -!- SUBUNIT: Interacts with the serine/threonine protein kinases MKNK1 and
CC       MKNK2 (PubMed:9878069). Binds EIF4A and EIF3 (PubMed:9049310,
CC       PubMed:9030685). Interacts with MIF4GD (PubMed:18025107). Interacts
CC       with DAZAP2 (PubMed:17984221). {ECO:0000269|PubMed:17984221,
CC       ECO:0000269|PubMed:18025107, ECO:0000269|PubMed:9030685,
CC       ECO:0000269|PubMed:9049310, ECO:0000269|PubMed:9878069}.
CC   -!- INTERACTION:
CC       P78344; P20042: EIF2S2; NbExp=4; IntAct=EBI-296519, EBI-711977;
CC       P78344; P60842: EIF4A1; NbExp=3; IntAct=EBI-296519, EBI-73449;
CC       P78344; P04792: HSPB1; NbExp=3; IntAct=EBI-296519, EBI-352682;
CC       P78344; PRO_0000308465 [P29991]; Xeno; NbExp=4; IntAct=EBI-296519, EBI-8826747;
CC       P78344-1; P60842: EIF4A1; NbExp=3; IntAct=EBI-16040248, EBI-73449;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P78344-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P78344-2; Sequence=VSP_038726;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed in all adult tissues
CC       examined, with high levels in skeletal muscle and heart. Also expressed
CC       in fetal brain, lung, liver and kidney. {ECO:0000269|PubMed:9030685,
CC       ECO:0000269|PubMed:9032289, ECO:0000269|PubMed:9049310}.
CC   -!- PTM: Phosphorylation; hyperphosphorylated during mitosis.
CC       {ECO:0000269|PubMed:11511540}.
CC   -!- MISCELLANEOUS: This gene has been shown to be extensively edited in the
CC       liver of APOBEC1 transgenic animal model. Its aberrant editing could
CC       contribute to the potent oncogenesis induced by overexpression of
CC       APOBEC1. The aberrant edited sequence, called NAT1, is likely to be a
CC       fundamental translational repressor.
CC   -!- SIMILARITY: Belongs to the eukaryotic initiation factor 4G family.
CC       {ECO:0000305}.
CC   -!- CAUTION: According to PubMed:9049310, this sequence initiates
CC       exclusively at a GTG codon. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB93515.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAD97268.1; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical GTG valine codon.; Evidence={ECO:0000305};
CC       Sequence=CAA61857.1; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical GTG valine codon.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U73824; AAB49973.1; -; mRNA.
DR   EMBL; U76111; AAC51166.1; -; mRNA.
DR   EMBL; X89713; CAA61857.1; ALT_SEQ; mRNA.
DR   EMBL; AK223548; BAD97268.1; ALT_SEQ; mRNA.
DR   EMBL; AC116535; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC014930; AAH14930.2; -; mRNA.
DR   EMBL; BC018746; AAH18746.1; -; mRNA.
DR   EMBL; BC018975; AAH18975.1; -; mRNA.
DR   EMBL; BC039851; AAH39851.1; -; mRNA.
DR   EMBL; BC043149; AAH43149.2; -; mRNA.
DR   EMBL; BC111415; AAI11416.1; -; mRNA.
DR   EMBL; BC111548; AAI11549.2; -; mRNA.
DR   EMBL; AB063323; BAB93515.1; ALT_INIT; mRNA.
DR   CCDS; CCDS31428.1; -. [P78344-1]
DR   CCDS; CCDS41618.1; -. [P78344-2]
DR   RefSeq; NP_001036024.3; NM_001042559.2. [P78344-2]
DR   RefSeq; NP_001166176.1; NM_001172705.1. [P78344-1]
DR   RefSeq; NP_001409.3; NM_001418.3. [P78344-1]
DR   PDB; 3D3M; X-ray; 1.90 A; A/B=730-897.
DR   PDB; 3L6A; X-ray; 2.00 A; A=540-897.
DR   PDB; 4IUL; X-ray; 2.30 A; A/B=61-323.
DR   PDBsum; 3D3M; -.
DR   PDBsum; 3L6A; -.
DR   PDBsum; 4IUL; -.
DR   AlphaFoldDB; P78344; -.
DR   SMR; P78344; -.
DR   BioGRID; 108297; 195.
DR   DIP; DIP-31366N; -.
DR   IntAct; P78344; 47.
DR   MINT; P78344; -.
DR   STRING; 9606.ENSP00000433664; -.
DR   GlyCosmos; P78344; 1 site, 1 glycan.
DR   GlyGen; P78344; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; P78344; -.
DR   MetOSite; P78344; -.
DR   PhosphoSitePlus; P78344; -.
DR   SwissPalm; P78344; -.
DR   BioMuta; EIF4G2; -.
DR   DMDM; 30315906; -.
DR   EPD; P78344; -.
DR   jPOST; P78344; -.
DR   MassIVE; P78344; -.
DR   MaxQB; P78344; -.
DR   PaxDb; P78344; -.
DR   PeptideAtlas; P78344; -.
DR   ProteomicsDB; 57574; -. [P78344-1]
DR   ProteomicsDB; 57575; -. [P78344-2]
DR   Antibodypedia; 1569; 488 antibodies from 40 providers.
DR   DNASU; 1982; -.
DR   Ensembl; ENST00000339995.11; ENSP00000340281.6; ENSG00000110321.19. [P78344-1]
DR   Ensembl; ENST00000396525.7; ENSP00000379778.3; ENSG00000110321.19. [P78344-2]
DR   Ensembl; ENST00000525681.6; ENSP00000433371.2; ENSG00000110321.19. [P78344-1]
DR   Ensembl; ENST00000526148.6; ENSP00000433664.2; ENSG00000110321.19. [P78344-1]
DR   GeneID; 1982; -.
DR   KEGG; hsa:1982; -.
DR   MANE-Select; ENST00000339995.11; ENSP00000340281.6; NM_001418.4; NP_001409.3.
DR   UCSC; uc057zbi.1; human. [P78344-1]
DR   AGR; HGNC:3297; -.
DR   CTD; 1982; -.
DR   DisGeNET; 1982; -.
DR   GeneCards; EIF4G2; -.
DR   HGNC; HGNC:3297; EIF4G2.
DR   HPA; ENSG00000110321; Low tissue specificity.
DR   MIM; 602325; gene.
DR   neXtProt; NX_P78344; -.
DR   OpenTargets; ENSG00000110321; -.
DR   PharmGKB; PA27723; -.
DR   VEuPathDB; HostDB:ENSG00000110321; -.
DR   eggNOG; KOG0401; Eukaryota.
DR   GeneTree; ENSGT00940000154675; -.
DR   InParanoid; P78344; -.
DR   OMA; LGHIRFV; -.
DR   OrthoDB; 92033at2759; -.
DR   PhylomeDB; P78344; -.
DR   PathwayCommons; P78344; -.
DR   Reactome; R-HSA-1169408; ISG15 antiviral mechanism.
DR   SignaLink; P78344; -.
DR   SIGNOR; P78344; -.
DR   BioGRID-ORCS; 1982; 519 hits in 1085 CRISPR screens.
DR   ChiTaRS; EIF4G2; human.
DR   EvolutionaryTrace; P78344; -.
DR   GeneWiki; EIF4G2; -.
DR   GenomeRNAi; 1982; -.
DR   Pharos; P78344; Tbio.
DR   PRO; PR:P78344; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P78344; protein.
DR   Bgee; ENSG00000110321; Expressed in visceral pleura and 208 other tissues.
DR   ExpressionAtlas; P78344; baseline and differential.
DR   Genevisible; P78344; HS.
DR   GO; GO:0005912; C:adherens junction; HDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016281; C:eukaryotic translation initiation factor 4F complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0003729; F:mRNA binding; IBA:GO_Central.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0008135; F:translation factor activity, RNA binding; IDA:UniProtKB.
DR   GO; GO:0003743; F:translation initiation factor activity; IDA:UniProtKB.
DR   GO; GO:0008219; P:cell death; TAS:ProtInc.
DR   GO; GO:0009059; P:macromolecule biosynthetic process; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:ProtInc.
DR   GO; GO:0006446; P:regulation of translational initiation; IDA:UniProtKB.
DR   CDD; cd11559; W2_eIF4G1_like; 1.
DR   Gene3D; 1.25.40.180; -; 3.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR045208; IF4G.
DR   InterPro; IPR003891; Initiation_fac_eIF4g_MI.
DR   InterPro; IPR003890; MIF4G-like_typ-3.
DR   InterPro; IPR003307; W2_domain.
DR   PANTHER; PTHR23253; EUKARYOTIC TRANSLATION INITIATION FACTOR 4 GAMMA; 1.
DR   PANTHER; PTHR23253:SF9; EUKARYOTIC TRANSLATION INITIATION FACTOR 4 GAMMA 2; 1.
DR   Pfam; PF02847; MA3; 1.
DR   Pfam; PF02854; MIF4G; 1.
DR   Pfam; PF02020; W2; 1.
DR   SMART; SM00515; eIF5C; 1.
DR   SMART; SM00544; MA3; 1.
DR   SMART; SM00543; MIF4G; 1.
DR   SUPFAM; SSF48371; ARM repeat; 3.
DR   PROSITE; PS51366; MI; 1.
DR   PROSITE; PS51363; W2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Direct protein sequencing;
KW   Initiation factor; Isopeptide bond; Methylation; Phosphoprotein;
KW   Protein biosynthesis; Reference proteome; Repressor;
KW   Translation regulation; Ubl conjugation.
FT   CHAIN           1..907
FT                   /note="Eukaryotic translation initiation factor 4 gamma 2"
FT                   /id="PRO_0000213325"
FT   DOMAIN          78..308
FT                   /note="MIF4G"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00698"
FT   DOMAIN          543..666
FT                   /note="MI"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00698"
FT   DOMAIN          720..904
FT                   /note="W2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00695"
FT   REGION          1..71
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          498..541
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        38..63
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         11
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         89
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         360
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         431
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         443
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         505
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   MOD_RES         508
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         514
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         902
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692"
FT   CROSSLNK        575
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         434..471
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_038726"
FT   VARIANT         236
FT                   /note="L -> M (in dbSNP:rs34885591)"
FT                   /id="VAR_048923"
FT   CONFLICT        169
FT                   /note="S -> P (in Ref. 2; AAC51166)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        233
FT                   /note="K -> Q (in Ref. 2; AAC51166)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        245
FT                   /note="K -> Q (in Ref. 2; AAC51166)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        351
FT                   /note="F -> L (in Ref. 2; AAC51166)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        441
FT                   /note="N -> S (in Ref. 6; AAH18746)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        531
FT                   /note="A -> G (in Ref. 2; AAC51166)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        534
FT                   /note="S -> N (in Ref. 6; AAH43149)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        613
FT                   /note="A -> G (in Ref. 2; AAC51166)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        861
FT                   /note="I -> S (in Ref. 2; AAC51166)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        899
FT                   /note="E -> G (in Ref. 2; AAC51166)"
FT                   /evidence="ECO:0000305"
FT   HELIX           68..86
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   TURN            90..92
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           93..103
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           108..124
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           126..128
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           129..142
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   TURN            149..152
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           162..182
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   STRAND          188..190
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           196..218
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   TURN            219..221
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           225..236
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   STRAND          240..242
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           244..246
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           248..265
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           268..270
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           271..282
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   TURN            283..286
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           292..306
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   TURN            307..309
FT                   /evidence="ECO:0007829|PDB:4IUL"
FT   HELIX           541..558
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           561..571
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           575..577
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           578..590
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           594..609
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           615..627
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           629..635
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           639..652
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           658..665
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           666..668
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   TURN            669..672
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           673..684
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           687..697
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           702..704
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           707..709
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           712..722
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           725..727
FT                   /evidence="ECO:0007829|PDB:3L6A"
FT   HELIX           731..743
FT                   /evidence="ECO:0007829|PDB:3D3M"
FT   HELIX           747..757
FT                   /evidence="ECO:0007829|PDB:3D3M"
FT   HELIX           760..764
FT                   /evidence="ECO:0007829|PDB:3D3M"
FT   HELIX           766..784
FT                   /evidence="ECO:0007829|PDB:3D3M"
FT   HELIX           799..820
FT                   /evidence="ECO:0007829|PDB:3D3M"
FT   HELIX           824..840
FT                   /evidence="ECO:0007829|PDB:3D3M"
FT   HELIX           847..857
FT                   /evidence="ECO:0007829|PDB:3D3M"
FT   HELIX           863..871
FT                   /evidence="ECO:0007829|PDB:3D3M"
FT   HELIX           880..895
FT                   /evidence="ECO:0007829|PDB:3D3M"
SQ   SEQUENCE   907 AA;  102362 MW;  4EF050B5EEA4DF91 CRC64;
     MESAIAEGGA SRFSASSGGG GSRGAPQHYP KTAGNSEFLG KTPGQNAQKW IPARSTRRDD
     NSAANNSANE KERHDAIFRK VRGILNKLTP EKFDKLCLEL LNVGVESKLI LKGVILLIVD
     KALEEPKYSS LYAQLCLRLA EDAPNFDGPA AEGQPGQKQS TTFRRLLISK LQDEFENRTR
     NVDVYDKREN PLLPEEEEQR AIAKIKMLGN IKFIGELGKL DLIHESILHK CIKTLLEKKK
     RVQLKDMGED LECLCQIMRT VGPRLDHERA KSLMDQYFAR MCSLMLSKEL PARIRFLLQD
     TVELREHHWV PRKAFLDNGP KTINQIRQDA VKDLGVFIPA PMAQGMRSDF FLEGPFMPPR
     MKMDRDPLGG LADMFGQMPG SGIGTGPGVI QDRFSPTMGR HRSNQLFNGH GGHIMPPTQS
     QFGEMGGKFM KSQGLSQLYH NQSQGLLSQL QGQSKDMPPR FSKKGQLNAD EISLRPAQSF
     LMNKNQVPKL QPQITMIPPS AQPPRTQTPP LGQTPQLGLK TNPPLIQEKP AKTSKKPPPS
     KEELLKLTET VVTEYLNSGN ANEAVNGVRE MRAPKHFLPE MLSKVIILSL DRSDEDKEKA
     SSLISLLKQE GIATSDNFMQ AFLNVLDQCP KLEVDIPLVK SYLAQFAARA IISELVSISE
     LAQPLESGTH FPLFLLCLQQ LAKLQDREWL TELFQQSKVN MQKMLPEIDQ NKDRMLEILE
     GKGLSFLFPL LKLEKELLKQ IKLDPSPQTI YKWIKDNISP KLHVDKGFVN ILMTSFLQYI
     SSEVNPPSDE TDSSSAPSKE QLEQEKQLLL SFKPVMQKFL HDHVDLQVSA LYALQVHCYN
     SNFPKGMLLR FFVHFYDMEI IEEEAFLAWK EDITQEFPGK GKALFQVNQW LTWLETAEEE
     ESEEEAD
//
